NYSE:AZNAstraZeneca Stock Price, Forecast & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZN stock has increased by 23.8% and is now trading at $55.19.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) issued its quarterly earnings results on Thursday, July, 30th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.04. The firm had revenue of $6.28 billion for the quarter, compared to analysts' expectations of $6.27 billion. AstraZeneca had a net margin of 8.36% and a return on equity of 37.72%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.73 EPS.
View AstraZeneca's earnings history.

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Investors of record on Friday, August 14th will be paid a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
View AstraZeneca's dividend history.

AstraZeneca shares split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

11 Wall Street analysts have issued 12 month price objectives for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they anticipate AstraZeneca's stock price to reach $61.67 in the next twelve months. This suggests a possible upside of 11.7% from the stock's current price.
View analysts' price targets for AstraZeneca.

News headlines about AZN stock have trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AstraZeneca earned a news sentiment score of 0.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about AstraZeneca.

AstraZeneca saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 1,920,000 shares, a decrease of 33.1% from the June 15th total of 2,870,000 shares. Based on an average daily volume of 4,970,000 shares, the days-to-cover ratio is presently 0.4 days.
View AstraZeneca's Short Interest.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Pfizer (PFE), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Zoetis (ZTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Moderna (MRNA), AT&T (T), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (1.82%), Jennison Associates LLC (1.49%), Fisher Asset Management LLC (0.64%), Bank of America Corp DE (0.32%), Winslow Capital Management LLC (0.23%) and Epoch Investment Partners Inc. (0.08%).
View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, FMR LLC, Winslow Capital Management LLC, Assetmark Inc., Cidel Asset Management Inc., Russell Investments Group Ltd., Hardman Johnston Global Advisors LLC, and Janney Capital Management LLC.
View insider buying and selling activity for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including Stifel Financial Corp, Fisher Asset Management LLC, Jennison Associates LLC, Avidity Partners Management LP, Bank of America Corp DE, Twin Tree Management LP, Ensign Peak Advisors Inc, and Marshall Wace North America L.P..
View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $55.19.

AstraZeneca has a market capitalization of $144.84 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]